SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) trades at a trailing P/E of 115.9. Trailing earnings yield is 0.86%.
Criteria proven by this page:
- VALUE (15/100, Fail) — trailing P/E is well above the S&P 500 average of ~25, suggesting a premium valuation (P/E 115.9); trailing earnings yield is below the 10-year Treasury yield (~4.3%), meaning bonds offer a better return (EY 0.86%).
- Trailing Earnings Yield 0.86% — below bond yields — investors are paying a premium for expected growth rather than current earnings.
Overall SharesGrow Score: 45/100 with 0/7 criteria passed.
SharesGrow 7-Criteria Score
✗
VALUE
15/100
Price-to-Earnings & upside
Proven by this page
~
HEALTH
50/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — BMYMP
Valuation Multiples
P/E (TTM)115.9
Forward P/EN/A
PEG RatioN/A
Forward PEGN/A
P/B Ratio0.00
P/S Ratio16.94
EV/EBITDA0.0
Per Share Data
EPS (TTM)$3.45
Book Value / Share$0.00
Revenue / Share$23.61
FCF / Share$0.00
Yields & Fair Value
Earnings Yield0.86%
Dividend Yield0.00%
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2016 |
$41.89 |
$19.43B |
$4.46B |
22.9% |
| 2017 |
$9.39 |
$20.78B |
$1.01B |
4.8% |
| 2018 |
$46.51 |
$22.56B |
$4.95B |
21.9% |
| 2019 |
$30.95 |
$26.15B |
$3.44B |
13.2% |
| 2020 |
$-84.38 |
$42.52B |
$-9B |
-21.2% |
| 2021 |
$65.61 |
$46.39B |
$6.99B |
15.1% |
| 2022 |
$45.43 |
$46.16B |
$6.33B |
13.7% |
| 2023 |
$59.44 |
$45.01B |
$8.03B |
17.8% |
| 2024 |
$-4.41 |
$48.3B |
$-8.95B |
-18.5% |
| 2025 |
$3.45 |
$48.19B |
$7.05B |
14.6% |
